Origin of COVID19 – Smoking Gun 2007 – Chapter 1 of 13
PDF of the 2007 gain-of-function-research publication, or link directly to the live publication the Journal of Virology.
Last Updated 20th May 2020.
Smoking Gun – 2007
In December 2007 the Wuhan Centre for Disease Control and Prevention (WCDCP), a Chinese state bio-weapons facility, working together with the Wuhan Institute of Virology (WIV), successfully mutated the SARS Corona Virus (SARS CoV), that they harvested from the tiny Horseshoe bat in the adjacent picture.
In this 2007 paper, published in the “Journal of Virology“, the head of the Wuhan Institute of Virology, Shi Zhengli and her team, described their replacement of the virus’s naturally occurring protein, with a protein that they manufactured. They explain that by replacing the proteins on the virus, they enabled the SARS CoV found in the sub-species Rhinolophus Peasonii, pictured above, to evade the natural human molecular blockade, and gain entry into human cells.
The 2007 paper pictured below, meticulously details the successful re-engineering process, that resulted in the successful infection of human cells. They also explain the specific molecular route, through which their re-engineered virus was able to infect humans. To ensure the paper does not disappear from the internet, you can access the PDF version saved on MRI’s servers.
First, they determined that the naturally occurring SARS CoV, or SARS-like Coronavirus (SL CoV), found in Rhinolophus Pearsonii, was completely unable to enter human cells naturally. They explain that infection of human cell lines was blocked by the “Angiotensin-Converting Enzyme 2”, known as “ACE2”.
They confirmed this natural protection of human cells by ACE2, each and every time that they re-engineered bat Coronaviruses, to enable them to infect human cells. Claims in medical journals or by medical professionals that COVID19 “likely, or probably, or could have, is thought to have” infected humans directly from bats, is baseless cover up theory that is refuted by repeated measurable and published fact by the Wuhan Institute of Virology, over the period of a decade and half.
Specifically the authors state: “Our results indicated that the SL-CoV S protein is unable to use ACE2 proteins of different species for cell entry and that SARS-CoV S protein also failed to bind the ACE2 molecule of the horseshoe bat, Rhinolophus pearsonii.”
To achieve the 2007 Corona Virus “breakthrough” into human cells, the Wuhan Institute of Virology, used biological products from the following animals, which they either harvested, mutated, and/or cloned at the Wuhan Institute of Virology, or purchased from the bio-weapons industry supply chain companies, listed below.
In humans, ACE2 would be referred to as “huACE2”. For the bat Rhinolophus Pearsonii, ACE2 would be referred to as “RpACE2”.
- “Rabbit polyclonal antibodies against ACE2 of the bat R. pearsonii (RpACE2) was generated … at the Wuhan Institute of Virology“
- “..goat anti-mouse immunoglobulin G (IgG) antibodies were purchased from Santa Cruz Biotechnology”
- “.. goat anti-rabbit IgG from Chemicon (Australia)”
- “… donkey anti-goat IgG from PTGLab (Chicago, IL).“
- The full-length S gene of a bat SL-CoV (Rp3) was cloned … using fecal samples from an R. pearsonii bat positive for SL-CoV“
By replacing the naturally occurring receptor binding domain, with a “hybrid”/”mutant” S protein, infection of human cells via ACE2, was achieved. They explain as follows:
“To define the minimal region required for this conversion from non-huACE2 binding to huACE2 binding, a series of CS proteins was constructed.”
“.. when the RBD of SL-CoV S was replaced with that from the SARS-CoV S, the hybrid S protein was able to use the huACE2 for cell entry“Tags: COVID-19